The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Self-citationMahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Laı̈, J.-L., Philippe, N., Facon, T., Fenaux, P., & Preudhomme, C. (2002) · Blood · doi:10.1182/blood.v100.3.1014 · Cited by 515
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
Bedi, A., Zehnbauer, B., Barber, J., Sharkis, S., & Jones, R. (1994) · Blood · doi:10.1182/blood.v83.8.2038.2038 · Cited by 508
le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P. G., Arlinghaus, R., & Pawson, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06319.x · Cited by 438
Gordon, M. Y., Dowding, C. R., Riley, G. P., Goldman, J. M., & Greaves, M. F. (1987) · Nature · doi:10.1038/328342a0 · Cited by 436
Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R. A., & Li, S. (2004) · Nature Genetics · doi:10.1038/ng1343 · Cited by 405
Self-citationWeisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
Self-citationArmstrong, S. A., Kung, A. L., Mabon, M. E., Silverman, L. B., Stam, R. W., Den Boer, M. L., Pieters, R., Kersey, J. H., Sallan, S. E., Fletcher, J. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00003-5 · Cited by 398
Self-citationImatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Hochhaus, A., & La Rosée, P. (2004) · Leukemia · doi:10.1038/sj.leu.2403426 · Cited by 336
Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S., & Druker, B. J. (2000) · Blood · doi:10.1182/blood.v96.9.3195 · Cited by 309
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Kelly, L. M., Yu, J.-C., Boulton, C. L., Apatira, M., Li, J., Sullivan, C. M., Williams, I., Amaral, S. M., Curley, D. P., Duclos, N., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00070-3 · Cited by 305
Self-citationRoots of Clinical Resistance to STI-571 Cancer Therapy
Barthe, C., Cony-Makhoul, P., Melo, J. V., & Mahon, J. R. F.-X. (2001) · Science · doi:10.1126/science.293.5538.2163a · Cited by 271
Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R., & Gilliland, D. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14845 · Cited by 268
Self-citationCorbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
Schwaller, J., Frantsve, J., Aster, J., Williams, I. R., Tomasson, M. H., Ross, T. S., Peeters, P., Van Rompaey, L., Van Etten, R. A., Ilaria, R., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5321 · Cited by 245
Self-citationOvercoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Hoover, R. R., Mahon, F.-X., Melo, J. V., & Daley, G. Q. (2002) · Blood · doi:10.1182/blood.v100.3.1068 · Cited by 241
Self-citationHofmann, W.-K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., & Koeffler, H. P. (2002) · Blood · doi:10.1182/blood.v99.5.1860 · Cited by 239
Mohi, M. G., Boulton, C., Gu, T.-L., Sternberg, D. W., Neuberg, D., Griffin, J. D., Gilliland, D. G., & Neel, B. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400063101 · Cited by 239
Self-citationBranford, Hughes, & Rudzki (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01749.x · Cited by 234
Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 227
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00108-9 · Cited by 216
Self-citationO'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. J. (1996) · PubMed · Cited by 182
Cowan-Jacob, S., Guez, V., Fendrich, G., Griffin, J., Fabbro, D., Furet, P., Liebetanz, J., Mestan, J., & Manley, P. (2004) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557043487321 · Cited by 163
Self-citationPhosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
Klejman, A., Rushen, L., Morrione, A., Słupianek, A., & Skórski, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205724 · Cited by 160
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML
O'Dwyer, M. E., Mauro, M. J., Kurilik, G., Mori, M., Balleisen, S., Olson, S. B., Magenis, E., Capdeville, R., & Druker, B. J. (2002) · Blood · doi:10.1182/blood-2002-03-0777 · Cited by 145
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
Melo, J. V., Myint, H., Galton, D. A. G., & Goldman, J. M. (1994) · PubMed · Cited by 143
Warmuth, M., Simon, N., Mitina, O., Mathes, R., Fabbro, D., Manley, P. W., Buchdunger, E., Forster, K., Moarefi, I., & Hallek, M. J. (2002) · Blood · doi:10.1182/blood-2002-01-0288 · Cited by 134
Self-citationMow, B. M. F., Chandra, J., Svingen, P. A., Hallgren, C. G., Weisberg, E., Kottke, T. J., Narayanan, V. L., Litzow, M. R., Griffin, J. D., Sausville, E. A., et al. (2002) · Blood · doi:10.1182/blood.v99.2.664 · Cited by 115
Self-citationNimmanapalli, R., O’Bryan, E., Huang, M., Bali, P., Burnette, P. K., Loughran, T. P., Tepperberg, J. H., Jove, R., & Bhalla, K. N. (2002) · PubMed · Cited by 112
Liu, Q., Schwaller, J., Kutok, J. L., Cain, D., Aster, J. C., Williams, I. R., & Gilliland, D. G. (2000) · The EMBO Journal · doi:10.1093/emboj/19.8.1827 · Cited by 110
Self-citationBcr-Abl inhibition as a modality of CML therapeutics
Buchdunger, E., Matter, A., & Druker, B. J. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00022-1 · Cited by 102
Rosée, P. G. L., Johnson, K. J., O'Dwyer, M. E., & Druker, B. J. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00836-6 · Cited by 95
Tipping, A. J., Mahon, F., Zafirides, G., Lagarde, V., Goldman, J. M., & Melo, J. (2002) · Leukemia · doi:10.1038/sj.leu.2402775 · Cited by 88
Sun, X., Layton, J. E., Elefanty, A. G., & Lieschke, G. J. (2001) · Blood · doi:10.1182/blood.v97.7.2008 · Cited by 77
Ricci, C., Scappini, B., Divoký, V., Gatto, S., Onida, F., Verstovšek, S., Kantarjian, H. M., & Beran, M. (2002) · PubMed · Cited by 75
Campbell, L. J., Patsouris, C., Rayeroux, K. C., Somana, K., Januszewicz, E. H., & Szer, J. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00615-5 · Cited by 72
Chronic myelogenous leukaemia with p185BCR/ABL expression: characteristics and clinical significance
Ravandi, F., Cortes, J. E., Albitar, M. X., Arlinghaus, R. B., Guo, J. Q., Talpaz, M., & Kantarjian, H. M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01736.x · Cited by 61
Barthe, C., Mj, G., Lagarde, V., Chollet, C., Cony‐Makhoul, P., Reiffers, J. J., Goldman, J. M., Melo, J. V., & Mahon, F. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03708.x · Cited by 43
Cited by
LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
Laskowski, R. A., & Swindells, M. B. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200227u · Cited by 6,471
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Metadata
- Authors
- Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Mohammed, A., Neuberg, D., Wright, R. D., Gilliland, D. G., & Griffin, J. D.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 7
- Issue
- 2
- Pages
- 129-141
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2124196948
- Cited by
- 1,492
- References
- 58
- FWCI
- 59.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.